| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National … M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 111 (12), 5446-5456, 2008 | 4161 | 2008 |
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ... The Lancet 376 (9747), 1164-1174, 2010 | 2487 | 2010 |
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ... New England Journal of Medicine 370 (11), 997-1007, 2014 | 2266 | 2014 |
| Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015 | 2229 | 2015 |
| Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions V Goede, K Fischer, R Busch, A Engelke, B Eichhorst, CM Wendtner, ... New England Journal of Medicine 370 (12), 1101-1110, 2014 | 1999 | 2014 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1848 | 2018 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1556 | 2012 |
| Mutations driving CLL and their evolution in progression and relapse DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ... Nature 526 (7574), 525-530, 2015 | 1233 | 2015 |
| Real-time single-molecule imaging of the infection pathway of an adeno-associated virus G Seisenberger, MU Ried, T Endress, H Buning, M Hallek, C Bräuchle Science 294 (5548), 1929-1932, 2001 | 1138 | 2001 |
| Multiple myeloma: increasing evidence for a multistep transformation process M Hallek, P Leif Bergsagel, KC Anderson Blood, The Journal of the American Society of Hematology 91 (1), 3-21, 1998 | 1048 | 1998 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 1024 | 2010 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 997 | 2021 |
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ... The lancet oncology 17 (6), 768-778, 2016 | 977 | 2016 |
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 970 | 2019 |
| Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia BF Eichhorst, R Busch, G Hopfinger, R Pasold, M Hensel, C Steinbrecher, ... Blood 107 (3), 885-891, 2006 | 947 | 2006 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 844 | 2016 |
| TP53 Mutation and Survival in Chronic Lymphocytic Leukemia T Zenz, B Eichhorst, R Busch, T Denzel, S Häbe, D Winkler, A Bühler, ... Journal of Clinical Oncology 28 (29), 4473-4479, 2010 | 815 | 2010 |
| First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10 … B Eichhorst, AM Fink, J Bahlo, R Busch, G Kovacs, C Maurer, E Lange, ... The lancet oncology 17 (7), 928-942, 2016 | 781* | 2016 |
| Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study M Augustin, P Schommers, M Stecher, F Dewald, L Gieselmann, H Gruell, ... The Lancet Regional Health–Europe 6, 2021 | 779 | 2021 |
| Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ... The Lancet 379 (9828), 1791-1799, 2012 | 776 | 2012 |
Stephan StilgenbauerProfessor of Medicine, Ulm University, Ulm, Germanyuniklinik-ulm.de의 이메일 확인됨